

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 55.00

Complete if Known

| | |
|----------------------|-----------------------|
| Application Number | 09/972772-Conf. #4878 |
| Filing Date | October 5, 2001 |
| First Named Inventor | Gary L. OLSON |
| Examiner Name | J. E. Russel |
| Art Unit | 1654 |
| Attorney Docket No. | PPI-106CP |

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number

12-0080

Deposit Account Name

Lahive & Cockfield, LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

| Fee Code | Fee (\$) | Fee Code | Fee (\$) | Fee Description | Fee Paid |
|----------|----------|----------|----------|------------------------|----------|
| 1001 | 770 | 2001 | 385 | Utility filing fee | |
| 1002 | 340 | 2002 | 170 | Design filing fee | |
| 1003 | 530 | 2003 | 265 | Plant filing fee | |
| 1004 | 770 | 2004 | 385 | Reissue filing fee | |
| 1005 | 160 | 2005 | 80 | Provisional filing fee | |

SUBTOTAL (1) (\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims 59 -60** = x = 0.00

Independent Claims 8 -8** = x = 0.00

Multiple Dependent

Large Entity Small Entity

| Fee Code | Fee (\$) | Fee Code | Fee (\$) | Fee Description |
|----------|----------|----------|----------|--|
| 1202 | 18 | 2202 | 9 | Claims in excess of 20 |
| 1201 | 86 | 2201 | 43 | Independent claims in excess of 3 |
| 1203 | 290 | 2203 | 145 | Multiple dependent claim, if not paid |
| 1204 | 86 | 2204 | 43 | ** Reissue independent claims over original patent |
| 1205 | 18 | 2205 | 9 | ** Reissue claims in excess of 20 and over original patent |

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

| Large Entity Fee Code | Large Entity Fee (\$) | Small Entity Fee Code | Small Entity Fee (\$) | Fee Description | Fee Paid |
|-----------------------|-----------------------|-----------------------|-----------------------|--|----------|
| 1051 | 130 | 2051 | 65 | Surcharge - late filing fee or oath | |
| 1052 | 50 | 2052 | 25 | Surcharge - late provisional filing fee or cover sheet. | |
| 1053 | 130 | 1053 | 130 | Non-English specification | |
| 1812 | 2,520 | 1812 | 2,520 | For filing a request for <i>ex parte</i> reexamination | |
| 1804 | 920* | 1804 | 920* | Requesting publication of SIR prior to Examiner action | |
| 1805 | 1,840* | 1805 | 1,840* | Requesting publication of SIR after Examiner action | |
| 1251 | 110 | 2251 | 55 | Extension for reply within first month | |
| 1252 | 420 | 2252 | 210 | Extension for reply within second month | |
| 1253 | 950 | 2253 | 475 | Extension for reply within third month | |
| 1254 | 1,480 | 2254 | 740 | Extension for reply within fourth month | |
| 1255 | 2,010 | 2255 | 1,005 | Extension for reply within fifth month | |
| 1401 | 330 | 2401 | 165 | Notice of Appeal | |
| 1402 | 330 | 2402 | 165 | Filing a brief in support of an appeal | |
| 1403 | 290 | 2403 | 145 | Request for oral hearing | |
| 1451 | 1,510 | 1451 | 1,510 | Petition to institute a public use proceeding | |
| 1452 | 110 | 2452 | 55 | Petition to revive - unavoidable | |
| 1453 | 1,330 | 2453 | 665 | Petition to revive - unintentional | |
| 1501 | 1,330 | 2501 | 665 | Utility issue fee (or reissue) | |
| 1502 | 480 | 2502 | 240 | Design issue fee | |
| 1503 | 640 | 2503 | 320 | Plant issue fee | |
| 1460 | 130 | 1460 | 130 | Petitions to the Commissioner | |
| 1807 | 50 | 1807 | 50 | Processing fee under 37 CFR 1.17(q) | |
| 1806 | 180 | 1806 | 180 | Submission of Information Disclosure Stmt | |
| 8021 | 40 | 8021 | 40 | Recording each patent assignment per property (times number of properties) | |
| 1809 | 770 | 2809 | 385 | Filing a submission after final rejection (37 CFR 1.129(a)) | |
| 1810 | 770 | 2810 | 385 | For each additional invention to be examined (37CFR 1.129(b)) | |
| 1801 | 770 | 2801 | 385 | Request for Continued Examination (RCE) | |
| 1802 | 900 | 1802 | 900 | Request for expedited examination of a design application | |
| Other fee (specify) | | Terminal Disclaimer | | | 55.00 |

*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 55.00

SUBMITTED BY

Name (Print/Type) Jane E. Remillard

Registration No. (Attorney/Agent)

38,872

(Complete (if applicable))

Telephone (617) 227-7400

Signature

Date

July 9, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 981583604US, in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 9, 2004

Signature:

(Jane E. Remillard)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 981 563 604 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/9 . 2004

Signature:

(Jane E. Remillard)

Docket No.: PPI-106CP
(PATENT)

JUL 19 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gary L. Olson, *et al.*

Application No.: 09/972772

Art Unit: 1653

Filed: October 5, 2001

Examiner: Jeffrey Russel

For: THERAPEUTIC AGENTS AND METHODS
OF USE THEREOF FOR THE MODULATION
OF ANGIOGENESIS

Confirmation No. 4878

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**TERMINAL DISCLAIMER**

Dear Sir:

I, Edgar W. Harlan, declare that I am the Senior Director of Intellectual Property and Licensing for Praecis Pharmaceuticals Incorporated a corporation of Delaware, having its principal place of business at 830 Winter Street, Waltham, MA, 02451-1420, the owner of the above-referenced application, as evidenced by the Assignment document recorded in the U.S. Patent and Trademark Office on March 21, 2002 at Reel 012760, Frame 0702, and that I am authorized to execute this terminal disclaimer on behalf of Praecis Pharmaceuticals Incorporated.

I further certify that I have reviewed the aforementioned Assignment document and believe, to the best of my knowledge, that title to the above-referenced patent application resides with the assignee, Praecis Pharmaceuticals Incorporated.

Pursuant to 35 U.S.C. §253 and 37 C.F.R. §1.321, Praecis Pharmaceuticals Incorporated hereby disclaims the terminal portion of any patent granted on the above-identified application,

07/14/2004 WABR/HAM 00000011 120080 09972772

01 FC:2814 55.00 DA

Serial No.: 09/895,443


- 2 -

Group Art Unit: 1653

which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,548,477, issued on April 15, 2003. Praecis Pharmaceuticals Incorporated also hereby agrees that any patent granted on the present application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,548,477. This terminal disclaimer applies to any patent granted on the present application and is binding upon the grantee, its successors or assignees.

Praecis Pharmaceuticals Incorporated does not disclaim any terminal part of any patent granted on the present application prior to the expiration date of the full statutory term of U.S. Patent No. 6,548,477 in the event that U.S. Patent No. 6,548,477 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutory disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.32(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer.

Signed this 9th day of July, 2004 by:



Name:

Edgar W. Harlan, Ph.D.

Title:

Senior Director, Intellectual Property and Licensing
Praecis Pharmaceuticals Incorporated